8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
Apr 7, 2026·SEC
Material company update
Apr 6, 2026·SEC
Soleno Therapeutics, Inc.(SLNO)Earnings, Financials & Key Ratios
SLNO•NASDAQ
$53.01
135.9× P/E·Price updated Jun 1, 2026
AboutSoleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Show more
- Revenue$190M
- EBITDA$17M+109.1%
- Net Income$21M+111.9%
- EPS (Diluted)0.39+108.9%
- Gross Margin98.58%
- EBITDA Margin8.91%
- Operating Margin7.85%
- Net Margin10.97%
- ROE6.01%+106.9%
SLNO Price & Volume
Soleno Therapeutics, Inc. (SLNO) stock price & volume — 10-year historical chart
Loading chart...
Milestone Revenue Masks Underlying Clinical Development Risks
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Moderate
Financial:Adequate
Cash Flow:Improving
Primary Risk:Binary regulatory approval dependency
Key Thesis Takeaways
- Soleno Therapeutics is currently navigating a transition from a clinical-stage entity to a potential commercial player, though its recent financial performance is heavily distorted by non-recurring milestone payments.
- While the company reported a net income of $31.4M in 2026Q1, the lack of consistent, organic revenue streams necessitates caution regarding long-term earnings durability.
- Investors should monitor the company's ability to sustain its $11.3M quarterly R&D investment as it moves toward regulatory milestones, given the persistent $400.0M deficit in retained earnings.
Verdict Logic
while the company achieved a 27.4% free cash flow margin in 2026Q1, the reliance on non-recurring revenue and the binary nature of clinical trial outcomes warrant a cautious, wait-and-see approach.
SLNO Growth Metrics
Soleno Therapeutics, Inc. (SLNO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years85.84%
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM148.45%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM138.24%
Return on Capital
10 Years-83.4%
5 Years-59.56%
3 Years-39.41%
Last Year3.67%
SLNO Recent Earnings
Soleno Therapeutics, Inc. (SLNO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 2/12 qtrs (50%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.59-19.2%
$0.73
Rev
$95M+0.9%
$94M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.80+25.0%
$0.64
Rev
$92M+3.4%
$89M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.47+717.4%
$0.06
Rev
$66M-25.4%
$89M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.09+83.0%
$0.53
Rev
$33M-17.0%
$39M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.59vs $0.73-19.2% | $95Mvs $94M+0.9% |
| Q1 2026 | Feb 25, 2026 | $0.80vs $0.64+25.0% | $92Mvs $89M+3.4% |
| Q4 2025 | Nov 4, 2025 | $0.47vs $0.06+717.4% | $66Mvs $89M-25.4% |
| Q3 2025 | Aug 6, 2025 | $0.09vs $0.53+83.0% | $33Mvs $39M-17.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Soleno Therapeutics, Inc. (SLNO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $53.01 | $2.76B | 135.92 | — | 10.97% | 6.01% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $114.46 | $7.84B | -36.80 | 45.83% | -93.84% | -204.35% | — | |
| $545.36 | $12.57B | -42.44 | 432.05% | -27.32% | -50.15% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — |
Compare SLNO vs Peers
Soleno Therapeutics, Inc. (SLNO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SLNO SEC Filings & Documents
Soleno Therapeutics, Inc. (SLNO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SLNO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SLNO Frequently Asked Questions
Soleno Therapeutics, Inc. (SLNO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Soleno Therapeutics, Inc.'s revenue?
Soleno Therapeutics, Inc. (SLNO) reported $285.0M in revenue for fiscal year 2025.
Is SLNO profitable?
Yes, Soleno Therapeutics, Inc. (SLNO) is profitable, generating $96.0M in net income for fiscal year 2025 (11.0% net margin).
Dividend & Returns
What is SLNO's return on equity?
Soleno Therapeutics, Inc. (SLNO) has a return on equity (ROE) of 6.0%. This is below average, suggesting room for improvement.
What is Soleno Therapeutics, Inc.'s free cash flow?
Soleno Therapeutics, Inc. (SLNO) generated $105.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.